Alliancebernstein L.P. Sells 3,580 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Alliancebernstein L.P. decreased its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 1.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 182,690 shares of the company’s stock after selling 3,580 shares during the period. Alliancebernstein L.P.’s holdings in Organogenesis were worth $585,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ORGO. Virtu Financial LLC purchased a new stake in shares of Organogenesis in the 4th quarter worth about $38,000. Palumbo Wealth Management LLC purchased a new position in shares of Organogenesis during the fourth quarter valued at about $65,000. SG Americas Securities LLC raised its stake in Organogenesis by 66.4% in the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company’s stock worth $134,000 after buying an additional 16,660 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Organogenesis by 194.2% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 47,406 shares of the company’s stock valued at $152,000 after purchasing an additional 31,290 shares during the period. Finally, Cornerstone Investment Partners LLC purchased a new stake in Organogenesis in the fourth quarter worth $162,000. Institutional investors own 49.57% of the company’s stock.

Insider Buying and Selling at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 36.90% of the stock is owned by company insiders.

Organogenesis Trading Down 0.7 %

NASDAQ ORGO opened at $4.22 on Friday. Organogenesis Holdings Inc. has a 12 month low of $2.17 and a 12 month high of $6.71. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The stock’s fifty day moving average price is $4.39 and its 200-day moving average price is $3.73. The stock has a market cap of $535.21 million, a P/E ratio of -70.33 and a beta of 1.79.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley boosted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.